Impacts of genomic alterations on the efficacy of HER2-targeted antibody-drug conjugates in patients with metastatic breast cancer.

J Transl Med · 2025 · PMC11730523 · PMID 39806366

Europe PMC DOI

hedged sentence

0.0570

closest p · 1.1× alpha

0.0570

boldest claim

The sentences

did not reach statistical significancep = 0.057so close (0.05 < p ≤ 0.1)

3 C), while patients with HER2-low disease also had poorer response but did not reach statistical significance (3.37 months vs. 6.47 months; HR = 2.60; 95% CI 0.93–7.27; p = 0.057) (Fig. 3 D).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.